Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Weight Gain

Weight Gain

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials for Weight Gain

20 trials tracked for Weight Gain: 4 in phase 3 or 4 and 1 with published results. The most-cited published study has 10 citations.

20Trials tracked
4Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 4 3 Phase 3 1 Phase 2 3 Other / NA 13
  1. Phase 4 Exenatide for the Treatment of Weight Gain Associated With Olanzapine in Obese Adults Completed · 10 cited
  2. Phase 4 Demonstrate the Effects of Pramlintide on Weight Reduction in Schizophrenia Completed
  3. Phase 4 Topiramate vs. Placebo in Preventing Weight Gain in Bipolar Disorder Treated With Olanzapine Completed
  4. Phase 3 Drug Exposure and Depot Medroxyprogesterone Acetate (DMPA) in Adolescent Subjects Completed
  5. Phase 2 Strategies to Reduce Antipsychotic-Associated Weight Gain in Youth Completed
  6. Phase 2 Study to Evaluate ARD-101 in Adults Receiving Bariatric Surgery Completed
Show 14 more trials
  1. Phase 2 Lorcaserin for Preventing Weight Gain Among Smokers Completed
  2. N/A Dietary Essential Fatty Acid Regulation of Omega-3 HUFA Metabolism; Satiety and Body Composition Completed
  3. N/A Role of Peanuts in Healthy Weight Gain in Athletic Individuals Completed
  4. N/A Gestational Weight Gain and Postpartum Weight Loss in Active Duty Women (Moms Fit 2 Fight) Completed
  5. N/A Online Food and Beverage Labels and Vending Machine Selections Completed
  6. N/A Implementing Effective, Collaborative Care for Schizophrenia (EQUIP-2) Completed
  7. N/A Healthy Lifestyles for Mentally Ill People Who Have Experienced Weight Gain From Their Antipsychotic Medications - 2 Completed
  8. N/A Eating Mindfully to Prevent Weight Regain Completed
  9. N/A The GEM (Goals for Eating and Moving) Study Completed
  10. N/A Maternal-Offspring Metabolics:Family Intervention Trial Completed
  11. N/A Study of Novel Approaches for Prevention Completed
  12. N/A Neurobehavioral Plasticity to Regular Sugar-Sweetened Beverage Intake: An fMRI Experiment Completed
  13. N/A A Study to Evaluate the Effects of a Dietary Supplement on Children's Health and Development Outcomes. Completed
  14. N/A Healthy Lifestyles for Mentally Ill People Who Have Experienced Weight Gain From Their Antipsychotic Medications Completed

Showing the 20 most-cited and recently-updated of 20 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found For clinicians

Weight Gain: what the trials found

Clinical trials have evaluated several pharmacological interventions for weight management, including Exenatide 1 and Pramlintide 2. Additionally, Topiramate was investigated in the context of weight-related outcomes 3.

In a study evaluating Depot medroxyprogesterone acetate (DMPA), 1 to 2 participants in each treatment arm experienced over 5% weight gain at 24 weeks 4. This trial also reported specific changes in bone mineral density (BMD) for the lumbar spine and total hip 4.

Recent results — preliminary, needs further review

  • Mindfulness Orientated Recovery Enhancement showed significant differences in body weight between groups (2.45 vs -3.78, p<0.001) 8.
  • NuBest Tall Growth Protein Powder did not show statistically significant changes in several cognitive or developmental metrics (p>0.05) 9.

For the clinician treating this condition

  • Pharmacological agents such as Exenatide, Pramlintide, and Topiramate are established interventions studied for weight management [1, 2, 3].
  • In patients receiving Depot medroxyprogesterone acetate (DMPA), a small proportion of participants experienced more than 5% weight gain at the 24-week mark 4.

AI synthesis of 6 cited trials, updated Jun 22, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Psychotropic medications frequently cause metabolic adverse effects via gut-brain axis
Psychiatry Sys. Review
Psychotropic medications frequently cause metabolic adverse effects via gut-brain axis Why do psychiatric medications often cause weight gain and diabetes?
A narrative review synthesizes emerging evidence on psychotropic-induced metabolic disturbances.
Psychiatric drugs often cause weight gain and diabetes by disrupting the gut-brain-metabolic axis, a link new science is starting to map.
Frontiers Apr 2, 2026